Clinical TrialID 5314
A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
NCT02120924
Rosacea
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 5314
- Evidence Id
- 5314
- Core Evidence Id
- 5314
- Source Clinical Trial Id
- 5299
- Herb2 Clinical Trial Id
- HBCT005299
- Nct Id
- NCT02120924
- Title
- A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
- Status
- Completed
- Phase
- Phase 3
- Study Result
- Yes
- Study Condition
- Rosacea
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
- Intervention
- DRUG: Azelaic acid|DRUG: Vehicle|DRUG: Finacea
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Triple
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 1009
- Outcome Measure
- Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts., Percent change from baseline to Week 12 in the inflammatory (papules and pustules) lesion counts in PP population., Baseline to Week 12
- Sponsor Collaborator
- Actavis Inc.
- Funded By
- INDUSTRY
- Location
- Site 24, Fremont, California, United States|Site 22, Santa Monica, California, United States|Site 1, Brandon, Florida, United States|Site 3, Fort Myers, Florida, United States|Site 27, Jacksonville, Florida, United States|Site 19, Miami, Florida, United States|Site 9, Miami, Florida, United States|Site 29, Miramar, Florida, United States|Site 2, Tampa, Florida, United States|Site 15, Chicago, Illinois, United States|Site 4, Plainfield, Indiana, United States|Site 14, Lake Charles, Louisiana, United States|Site 17, Glenn Dale, Maryland, United States|Site 6, Bay City, Michigan, United States|Site 30, Clinton Township, Michigan, United States|Site 16, Las Vegas, Nevada, United States|Site 11, Raleigh, North Carolina, United States|Site 23, Winston-Salem, North Carolina, United States|Site 26, Philadelphia, Pennsylvania, United States|Site 12, Warwick, Rhode Island, United States|Site 28, Simpsonville, South Carolina, United States|Site 20, Nashville, Tennessee, United States|Site 21, College Station, Texas, United States|Site 5, Dallas, Texas, United States|Site 8, El Paso, Texas, United States|Site 13, Houston, Texas, United States|Site 7, Katy, Texas, United States|Site 18, Salt Lake City, Utah, United States|Site 10, Norfolk, Virginia, United States|Site 25, University Place, Virginia, United States
- Other Id
- 13-1014
- Start Date
- 2013-07
- Primary Completion Date
- 2014-09
- Completion Date
- 2014-09
- First Posted
- 2014-04-23
- Results First Posted
- 2020-06-02
- Last Update Posted
- 2020-06-02
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT02120924
- Title Cn
- Title En
- A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
- Bilingual Status
- semi_complete